These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16956903)

  • 41. Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens.
    Goudah A
    Br Poult Sci; 2009 Mar; 50(2):251-8. PubMed ID: 19373726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Penetration of moxifloxacin into rat mandibular bone and soft tissue.
    Cachovan G; Nergiz I; Thuss U; Siefert HM; Sobottka I; Oral O; Platzer U; Dogan-Onur O
    Acta Odontol Scand; 2009; 67(3):182-6. PubMed ID: 19306136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep.
    Cárceles CM; Escudero E; Fernández-Varón E; Marín P
    Vet J; 2009 Jun; 180(3):343-7. PubMed ID: 18406644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery.
    Ong-Tone L
    J Cataract Refract Surg; 2008 May; 34(5):819-22. PubMed ID: 18471639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery.
    De Smet J; Colin P; De Paepe P; Ruige J; Batens H; Van Nieuwenhove Y; Vogelaers D; Blot S; Van Bocxlaer J; Van Bortel LM; Boussery K
    J Antimicrob Chemother; 2012 Jan; 67(1):226-9. PubMed ID: 21987240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing.
    Gardner SY; Davis JL; Jones SL; LaFevers DH; Hoskins MS; McArver EM; Papich MG
    J Vet Pharmacol Ther; 2004 Feb; 27(1):57-60. PubMed ID: 14995968
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
    Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
    Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic variables of moxifloxacin in healthy male camels following intravenous and intramuscular administration.
    Abd El-Aty AM; Goudah A; Shah SS; Shin HC; Shimoda M; Shim JH
    J Vet Pharmacol Ther; 2007 Dec; 30(6):586-91. PubMed ID: 17991229
    [No Abstract]   [Full Text] [Related]  

  • 49. Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study.
    de Smet J; Colpaert K; de Paepe P; van Bocxlaer J; Decruyenaere J; Boussery K
    Scand J Infect Dis; 2012 Nov; 44(11):874-8. PubMed ID: 22804100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.
    Simon N; Sampol E; Albanese J; Martin C; Arvis P; Urien S; Lacarelle B; Bruguerolle B
    Clin Pharmacol Ther; 2003 Oct; 74(4):353-63. PubMed ID: 14534522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statistical characteristics of moxifloxacin-induced QTc effect.
    Yan LK; Zhang J; Ng MJ; Dang Q
    J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Good penetration of moxifloxacin into human abscesses.
    Sauermann R; Karch R; Kjellsson MC; Feurstein T; Püspök A; Langenberger H; Böhmdorfer M; Jäger W; Zeitlinger M
    Pharmacology; 2012; 90(3-4):146-50. PubMed ID: 22868236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
    Hariprasad SM; Shah GK; Chi J; Prince RA
    J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.
    Rink AD; Stass H; Delesen H; Kubitza D; Vestweber KH
    Clin Drug Investig; 2008; 28(2):71-9. PubMed ID: 18211115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.
    Lindstrom R; Lane S; Cottingham A; Smith S; Sall K; Silverstein S; Shettle L; Walters T; Faulkner R; Cockrum P; Teuscher N
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract.
    Schwab D; Grauer M; Hahn EG; Mühldorfer S
    Aliment Pharmacol Ther; 2005 Sep; 22(5):417-22. PubMed ID: 16128679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort.
    Majcher-Peszynska J; Sass M; Schipper S; Czaika V; Gussmann A; Lobmann R; Mundkowski RG; Luebbert C; Kujath P; Ruf BR; Koch H; Schareck W; Klar E; Drewelow B;
    Eur J Clin Pharmacol; 2011 Feb; 67(2):135-42. PubMed ID: 20871984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.